Generic launch was impossible, says Impax

Impax has argued in court that although it had bottled $1.5 million worth of Oxymorphone by June 2010, it wasn’t prepared to launch at risk because the company hadn’t made enough of the drug to last a month in the market.

Unlock unlimited access to all Global Competition Review content